NCT06480552View on ClinicalTrials.gov

An Open-label Dose Escalation/Expansion Trial to Evaluate the Safety and Anti-tumor Activity of TEV-56278 Alone or in Combination With Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors

PHASE1RecruitingINTERVENTIONAL
Enrollment

240

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

May 26, 2029

Study Completion Date

February 25, 2031

Conditions
Advanced Solid Tumors
Interventions
DRUG

TEV-56278

Administered intravenously

DRUG

Pembrolizumab

Administered intravenously

Trial Locations (11)

15232

RECRUITING

Teva Investigational Site 12058, Pittsburgh

22031

RECRUITING

Teva Investigational Site 12018, Fairfax

28078

RECRUITING

Teva Investigational Site 12014, Huntersville

32746

RECRUITING

Teva Investigational Site 12021, Lake Mary

37203

RECRUITING

Teva Investigational Site 12019, Nashville

45219

RECRUITING

Teva Investigational Site 12023, Cincinnati

48201

RECRUITING

Teva Investigational Site 12015, Detroit

53226

RECRUITING

Teva Investigational Site 12025, Milwaukee

60611

RECRUITING

Teva Investigational Site 12016, Chicago

90025

RECRUITING

Teva Investigational Site 12017, Los Angeles

M5G 2M9

RECRUITING

Teva Investigational Site 11282, Toronto

All Listed Sponsors
lead

Teva Branded Pharmaceutical Products R&D, Inc.

INDUSTRY